A5078568032- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Prostate Cancer Treatment and Research
- Head and Neck Cancer Studies
- Lung Cancer Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Virus-based gene therapy research
- Patient-Provider Communication in Healthcare
- PI3K/AKT/mTOR signaling in cancer
- Cancer Treatment and Pharmacology
- Palliative Care and End-of-Life Issues
- Management of metastatic bone disease
- Cancer survivorship and care
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Respiratory viral infections research
- Radiopharmaceutical Chemistry and Applications
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Global Cancer Incidence and Screening
- Myasthenia Gravis and Thymoma
- Cancer therapeutics and mechanisms
- Brain Metastases and Treatment
- Renal cell carcinoma treatment
- Cancer-related cognitive impairment studies
Philips (United States)
2024
Queen's University
1999-2023
Kingston Health Sciences Centre
2019-2022
Queens University
2022
Paracelsus Medical University
2019
Health Net
2018
Kingston General Hospital
2001-2017
Queen Elizabeth Hospital Birmingham
2014
Cancer Care South East
2013
Regional Cancer Center
2010
PURPOSE To identify the major sites of platinum accumulation within neural tissues after treatment with cisplatin and to determine relationship between cumulative dosage, time, development histopathological clinical neurotoxicity. PATIENTS AND METHODS Twenty-one patients treated antemortem had tissue harvested at autopsy. Neural were assayed for examined histopathologic evidence The neurotoxicity various pharmacologic parameters was analyzed. RESULTS Tissue levels found be highest in dorsal...
To evaluate the efficacy and safety of multitargeted antifolate LY231514 (MTA) in patients receiving initial chemotherapy for unresectable, advanced non-small-cell lung cancer (NSCLC).Patients with measurable, NSCLC who had not received previous disease were considered this study. Eligible gave written informed consent initially MTA 600 mg/m(2) intravenously (IV) 10 minutes every 3 weeks. After three treatment at dose, dose was reduced to 500 IV same infusion time frequency because toxicity...
This double-blind randomized phase II trial examined whether vandetanib, an inhibitor of vascular endothelial and epidermal growth factor receptors, could prolong progression-free survival in responding patients with small-cell lung cancer.Eligible complete response (CR) or partial (PR) to combination chemotherapy (+/- thoracic prophylactic cranial radiation) received oral vandetanib 300 mg/d matched placebo. With 100 77 events, the study had 80% power detect improvement median from 4 6.5...
Results of a study comparing pain control outcomes with preoperative oral versus intraoperative i.v. acetaminophen use in adults undergoing total hip or knee arthroplasty are reported.A single-center, randomized, placebo-controlled, equivalence trial was conducted. Patients were assigned (1:1) to receive 2 500-mg capsules before surgery, an placebo infusion during surgery (the group), followed by 1,000 mg/100 mL group). after postanesthesia care unit (PACU) admission up 24 hours...
To determine the frequency of clinically important complications femoral venous catheters.Prospective survey major and minor complications.A mixed medical/surgical ICU in a university hospital.One hundred twenty-three patients admitted to who underwent catheterization over 2-yr period.There were 150 catheters inserted 123 for mean duration 6.4 days. There no including catheter-related sepsis. Minor consisted arterial puncture (9.3%), local bleeding (10%), inflammation (4.7%). Critical care...
Objectives: Lapatinib (GW572016) is a selective and potent dual tyrosine kinase inhibitor of the epidermal growth factor 1 (EGFR) 2 (HER2), approved in treatment HER2 positive breast cancer. Since EGFR overexpression has also been seen prostate cancer appears to correlate with worse clinical outcome, may represent novel therapeutic strategy This Phase II multicenter trial first evaluate early stage, hormonally untreated recurrent or metastatic Methods: Eligible patients received lapatinib...
We used continuous positive airway pressure (CPAP) by face mask to treat 18 AIDS patients with Pneumocystis carinii pneumonia (PCP) who were in hypoxic respiratory failure. Candidates for CPAP conscious, not hypercarbic, and able protect their on ICU admission. Treatment was effective well tolerated. Mean Po2 rose from 62 158 torr, rate decreased 51 32 breath/min, Pco2 unchanged. duration of treatment 4.5 days. Only one patient developed a pneumothorax; there no other major complications....
BACKGROUND Because multiple treatments are available for metastatic castrate‐resistant prostate cancer (mCRPC) and most patients elderly, the prediction of toxicity risk is important. The Cancer Aging Research Group (CARG) tool predicts chemotherapy in older adults with mixed solid tumors, but has not been validated mCRPC. In this study, its ability to predict docetaxel (CHEMO) was validated, utility examined predicting abiraterone or enzalutamide (A/E) among METHODS Men aged 65+ years were...
PURPOSE: Many patients with locally advanced non–small-cell lung cancer (LA-NSCLC) are eligible for combined-modality therapy (CMT; chemotherapy and radiotherapy). Although CMT offers slightly higher chances of survival than radiotherapy alone (RT), it also carries a probability toxicity, raising the possibility that some may prefer to decline CMT. We report pilot study decision aid designed in this setting. PATIENTS AND METHODS: The included structured description treatment options...
IntroductionIn the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of lung progressing during or after platinum-based chemotherapy. Patient-reported outcomes (PROs) health-related quality life (QoL) these are presented.Patients MethodsPatients (n = 795) were randomized 1:1 to oral (40 mg/d) (150 mg/d). PROs collected (baseline, every 28 days until progression,...
Timely lung cancer care has been associated with improved clinical outcomes and patient satisfaction. We identified improvement opportunities in management pathways at Kingston Health Sciences Centre. Quality strategies led to the implementation of a multidisciplinary clinic (MDC).We set an outcome measure decreasing time from diagnosis first treatment by 10 days within 6 months implementation. implemented weekly MDC that involved respirologists, medical oncologists, radiation oncologists...
// Bernhard Josef Eigl 1 , Kim Chi Dongsheng Tu 2 Sebastien J. Hotte 3 Eric Winquist 4 Christopher M. Booth 5 Christina Canil 6 Kylea Potvin Richard Gregg Scott North 7 Muhammad Zulfiqar Susan Ellard 8 Joseph Dean Ruether 9 Lyly Le 10 A. Saranya Kakumanu 11 Mohammad Salim 12 Alison L. Allan Harriet Feilotter Ashley Theis and Lesley Seymour BC Cancer Agency, Vancouver, BC, Canada Canadian Trials Group, Kingston, ON, Juravinski Centre, Hamilton, London Health Sciences London, Centre of...
Clinical practice guidelines (cpgs) are systematically developed statements designed to assist practitioners and patients in making decisions about appropriate heath care interventions. expensive time-consuming create. A cpg on concurrent chemotherapy with radiation therapy (ccrt) was Ontario at a time when treatment approaches for head-and-neck cancer were changing significantly.An assessment of treatments outcomes based electronic chart data obtained from population-based study 571...
<h3>Importance</h3> Older adults are at greater risk of cognitive decline with various oncologic therapies. Some commonly used therapies for advanced prostate cancer, such as enzalutamide, have been linked to impairment, but published data scarce, come from single-group studies, or focus on self-reported cognition. <h3>Objective</h3> To longitudinally examine the association between function and docetaxel (chemotherapy), abiraterone, radium Ra 223 dichloride (radium 223) in older men...
Purpose To describe the structure and use of a decision aid for patients with locally advanced non‐small cell lung cancer (LA‐NSCLC) who are eligible combined‐modality treatment (CMT) or radiotherapy alone (RT). Methods The included structured description options trade‐off exercises designed to help clarify patient’s values relevant outcomes by determining survival advantage threshold (the increase in conferred CMT over RT that patient deemed necessary choosing CMT). Additional outcome...